HUTCHMED (China) Limited ADR(HCM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | - | P/E | 126.06 | EPS (ttm) | 0.1 | Insider Own | 2.3% | Shs Outstand | 174.5M | Perf Week | -9.14% |
| Market Cap | 2.24B | Forward P/E | 25.6 | EPS next Y | 64.58% | Insider Trans | - | Shs Float | 170.5M | Perf Month | 4.65% |
| Enterprise Value | 0.97B | PEG | - | EPS next Q | 0.21 | Inst Own | 2.56% | Short Float | 0.12% | Perf Quarter | 20.04% |
| Income | 0.02B | P/S | 4.06 | EPS this Y | -88.3% | Inst Trans | 0.31% | Short Ratio | 3.07 | Perf Half Y | -9.65% |
| Sales | 0.55B | P/B | 1.77 | EPS next 5Y | - | ROA | 1.02% | Short Interest | 0.20M | Perf YTD | -3.83% |
| Book/sh | 7.23 | P/C | 1.63 | EPS past 3/5Y | - | ROE | 1.44% | 52W High | -29.95% ($18.30) | Perf Year | -21.69% |
| Cash/sh | 7.88 | P/FCF | 225.02 | Sales past 3/5Y | 8.89% 19.22% | ROIC | 1.34% | 52W Low | 31.22% ($9.77) | Perf 3Y | -14.25% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -96.21% | Gross Margin | 41.55% | Volatility(W/M) | 2.94% 2.25% | Perf 5Y | -67% |
| Dividend TTM | - | EV/Sales | 1.76 | Sales Y/Y TTM | -8.81% | Oper. Margin | -6.34% | ATR (14) | 0.41 | Perf 10Y | 2.56% |
| Dividend Ex-Date | - | Quick Ratio | 5.5 | EPS Q/Q | -88.2% | Profit Margin | 3.26% | RSI (14) | 53.08 | Recom | 1.32 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.64 | Sales Q/Q | 41.96% | SMA20 | 0.78% ($12.72) | Beta | 0.19 | Target Price | $20.1 |
| Payout | - | Debt/Eq | 0.07 | Earnings | 2026/7/30 | SMA50 | 7.22% ($11.96) | Rel Volume | 1.27 | Prev Close | $13.12 |
| Employees | 1796 | LT Debt/Eq | 0.06 | EPS/Sales Surpr. | -31.03% -8.51% | SMA200 | -2.95% ($13.21) | Avg Volume(3M) | 0.07M | Price | $12.82 |
| IPO | 2016/3/17 | Option/Short | Yes/Yes | Trades | 606 | Volume | 82,755 | Change | -2.29% |
Company
HCM is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 A China-based biopharmaceutical company focused on developing and commercializing innovative oncology drugs. It markets in-house developed drugs, including targeted oncology therapies, in China and global markets, maintains a late-stage clinical pipeline, and expands into overseas markets through partnerships with global pharmaceutical companies. It has established itself as a China-based oncology biopharma player with proprietary cancer drug development and commercialization capabilities.
Over the past 1 year, roughly in the middle
30% below its 1-year high.
HCM has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -88.3% this year.
Tap to view numbers
The price looks about right
Trading at 126.1 times earnings.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -14.3% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 2.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
MCHS 0.01%
ECNS 0.01%
CANC 0.00%
NSI 0.00%
FDTS 0.00%It ranks #4 in the industry
Based on market cap of $2B.
HCM $2B PER 126.1
TAK $58B PER -
TEVA $43B PER 62.4
HLN $40B PER 18.9
FAQ
What kind of company is HCM?
HCM belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of HCM?
The market cap of HCM is approximately $2.2B, ranking 2,002 within its sector.
What is the P/E ratio of HCM?
HCM has a P/E ratio of approximately 126.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for HCM?
HCM has recorded a 52-week high of $18.30 and a low of $9.77.
